
The present study compares the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin ± a second oral antihyperglycemic drug (OAD). LixiLan‐O‐AP (NCT03798054) was a 24‐week multicenter study in adults (n=878) with HbA1c ≥7 and ≤11% on OAD(s) randomized (2:2:1) to open‐label once‐daily iGlarLixi, iGlar, or Lixi on continued metformin ± sodium‐glucose co‐transporter‐2 inhibitor. iGlarLixi achieved significant HbA1c reductions, to near‐normoglycemic levels, compared with iGlar or Lixi, with no significant additional risk of hypoglycemia and mitigated body weight gain versus iGlar, with fewer gastrointestinal adverse events versus Lixi. iGlarLixi with specifically adapted ratios may provide an efficacious and well‐tolerated treatment option for Asian Pacific people with T2D.
Like
Save
Share